Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Beuvry – page 87

1 417 clinical trials in Beuvry, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Beuvry at a glance
1 417
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 417 trials in Beuvry

Open in trial search

Non-small cell lung cancer recurrent

Not recruiting

Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Francois Baclesse

Acute myeloid leukaemia+1

Not recruiting

Study of three different doses of busulfan with fludarabine and thymoglobuline in stem cell transplantation for patients with high-risk myeloid blood disorders

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Institut Paoli-Calmettes

Critical illness

Not recruiting

Study on Hydrocortisone and Fludrocortisone for Adults with Critical Illness-Related Corticosteroid Insufficiency

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tetracosactide
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary hypertension

Not recruiting

Study on the Effects of Riociguat and Macitentan in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer stage IV+3

Not recruiting

Study Comparing Ensartinib and Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Xcovery Holding Co. LLC

Plasma cell leukaemia

Not recruiting

Study on Daratumumab, Lenalidomide, and Dexamethasone for Patients with Primary Plasma Cell Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Assistance Publique Hopitaux De Paris

Breast cancer

Not recruiting

Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Alliance Foundation Trials LLC

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Follicular Lymphoma After Previous Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:DF1001
  • Sponsor:Dragonfly Therapeutics Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Letrozole
  • Sponsor:Solti Group

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neoplasm

Not recruiting

Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:iTeos Belgium

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Beuvry

What the registry says about research in the country

01 Oncology Research - Digestive System

Several groundbreaking trials focusing on gastrointestinal cancers, including studies evaluating novel treatments for esophageal squamous cell carcinoma and advanced colorectal cancer. Research includes innovative combination therapies and targeted treatments for specific genetic mutations.

  • Esophageal Cancer Treatment
  • Colorectal Cancer Therapies
  • Pancreatic Adenocarcinoma Studies
02 Respiratory and Lung Cancer Research

Innovative studies examining treatments for non-small cell lung cancer, including immunotherapy combinations and radiation therapy approaches. Research focuses on improving outcomes for patients with advanced disease stages.

  • Advanced NSCLC Treatments
  • Immunotherapy Combinations
  • Radiation Therapy Protocols
03 Prostate and Breast Cancer Studies

Comprehensive research into hormone-dependent cancers, investigating new treatment approaches for castrate-resistant prostate cancer and ER+/HER2- breast cancer. Studies include both early-stage and advanced disease management.

  • Prostate Cancer Therapeutics
  • Breast Cancer Treatments
  • Hormone Therapy Research
04 Infectious Disease and Critical Care

Studies examining treatments for respiratory tract infections and severe infections in intensive care settings. Research includes antibiotic alternatives and management strategies for septic shock.

  • Respiratory Infections
  • Antibiotic Studies
  • Critical Care Interventions
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.